

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>FISHER &amp; PAYKEL HEALTHCARE CORPORATION LIMITED</b>
<b>ABN</b>	<b>098 026 281</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>MICHAEL GRENFELL DANIELL</b>
<b>Date of last notice</b>	11 July 2014

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Not Applicable
<b>Date of change</b>	i) 28 August 2014 ii) 28 August 2014
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"><li>• Daniell Family Trust – 769,109 Trustee &amp; Beneficiary</li><li>• Michael Grenfell Daniell – 27,240 ordinary shares</li><li>• Michael Grenfell Daniell – 800,000 options to acquire ordinary shares</li><li>• Michael Grenfell Daniell – 60,000 Performance Share Rights</li><li>• Fisher &amp; Paykel Healthcare Employee Share Purchase Trust Ltd – Director of Trustee Company 650,176 ordinary shares</li></ul>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Ordinary Shares, Options and Performance Share Rights
<b>Number acquired</b>	i) 150,000 options ii) 50,000 Performance Share Rights
<b>Number disposed</b>	Not applicable
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	NZ\$Nil
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>• Daniell Family Trust – 769,109 Trustee &amp; Beneficiary</li> <li>• Michael Grenfell Daniell – 27,240 ordinary shares</li> <li>• Michael Grenfell Daniell – 950,000 options to acquire ordinary shares</li> <li>• Michael Grenfell Daniell – 110,000 Performance Share Rights</li> </ul> Fisher & Paykel Healthcare Employee Share Purchase Trustee Ltd – Director of Trustee Company 647,896 ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of 150,000 options to acquire ordinary shares. Issue of 50,000 Performance Share Rights. Adjustments where necessary to non-beneficial share trustee holdings, for minor movements.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

+ See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

<sup>+</sup> See chapter 19 for defined terms.



## Ongoing Disclosure Notice

### Disclosure of Directors and Officers Relevant Interests

Section 19T(2), Securities Markets Act 1988

#### A Details of director or officer

Name of director or officer of public issuer:	Michael Grenfell DANIELL
Name of public issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	Not Applicable
Position held in public issuer:	Managing Director/Chief Executive Officer

#### B Securities in public issuer or any related body corporate in which director or officer has relevant interest

Number, class, and type of securities:	i) 150,000 options to acquire ordinary shares ii) 50,000 Performance Share Rights
--	--

#### C Nature of relevant interest and name of registered holder

Nature of relevant interest in securities:	Beneficial Ownership
Name of registered holder of securities	Michael Grenfell DANIELL

#### D Details of acquisitions and disposals

*If the relevant interest was acquired—*

Date of acquisition	28 August 2014
Consideration paid for acquisition	NZ\$Nil

*If the relevant interest was disposed of—*


Date of disposal	Not applicable
Consideration received for disposal	Not applicable

#### Type of transaction

Describe the arrangement pursuant to which, or the circumstances in which, the acquisition or disposal took place	i) Issue of 150,000 options to acquire ordinary shares ii) Issue of 50,000 Performance Share Rights
---	--

E Total number of transactions this notice relates to	Two
F Date of last disclosure notice (whether in form 1 or form 2) by the director or officer	11 July 2014

#### G Signature

Signature of director or officer:	
Date of signature:	3 September 2014

or

Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	